Advances on mesenchymal stem cells in the treatment of refractory pulmonary diseases
10.3760/cma.j.cn101070-20200313-00390
- VernacularTitle:间充质干细胞治疗难治性肺疾病研究进展
- Author:
Zhou FU
1
;
Jingyi YOU
;
Lin ZOU
Author Information
1. 重庆医科大学附属儿童医院呼吸科 400014
- From:
Chinese Journal of Applied Clinical Pediatrics
2020;35(4):251-254
- CountryChina
- Language:Chinese
-
Abstract:
Refractory pulmonary disease is a respiratory disease that seriously threatens the health of patients, and can lead to impaired pulmonary function and even respiratory failure.Currently, conventional drug therapy does not work well, so it is particularly important to find more effective treatments.Mesenchymal stem cells(MSCs) are a kind of multifunctional stem cells, which can promote the repair of damaged cells by regulating inflammatory and immune reactions and boost the regeneration of damaged tissues through paracrine.Therefore, MSCs are expected to provide a possibility for the treatment of refractory lung pulmonary diseases.
